

Global Generic Drugs Market Report and Forecast 2023-2031

Market Report | 2023-05-06 | 147 pages | EMR Inc.

AVAILABLE LICENSES:

- Single User License \$5999.00
- Five User License \$7999.00
- Corporate License \$9999.00

Report description:

Global Generic Drug Market Report and Forecast 2023-2031

Global Generic Drugs Market Outlook

The global generic drugs market value was USD 411.8 billion in 2022, driven by the increasing demand for affordable medications across the globe. The market size is anticipated to grow at a CAGR of 5.5% during the forecast period of 2023-2031 to achieve a value of USD 666.8 billion by 2031.

Generic Drugs Introduction

Generic drugs are pharmaceutical products that have the same active ingredients, dosage form, strength, and route of administration as the branded drugs. They are developed and marketed after the patent expiry of the original branded drugs. The production and sale of generic drugs are usually much cheaper than their branded counterparts, making them an affordable option for patients.

The global generic drug market has witnessed steady growth over the years due to various factors such as the increasing prevalence of chronic diseases, the rise in the aging population, and the cost-effectiveness of these drugs. In addition, the patent expiry of several branded drugs has resulted in an increase in the number of generic drug approvals by regulatory bodies, further propelling market growth.

However, the market also faces challenges such as a lack of awareness about generic drugs in some regions, stringent regulatory policies, and the presence of counterfeit products. Nevertheless, ongoing research and development activities aimed at improving the safety and efficacy of generic drugs are expected to open up new growth opportunities for the market in the future.

Generic Drugs Market Scenario

Generic drugs are pharmaceuticals that have the same active ingredients, dosage, and strength as their brand-name counterparts, but are sold under their chemical name rather than a brand name. Generic drugs are typically less expensive than brand-name drugs and are considered a cost-effective alternative for patients who require ongoing medication therapy. The global market for generic drugs has been growing rapidly in recent years, driven by factors such as rising healthcare costs, increasing demand for affordable medications, and expiration of patents on branded drugs.

The market for generic drugs is highly competitive, with a large number of players operating in the space. Many pharmaceutical

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

companies have entered the market to capitalize on the growing demand for generic drugs, resulting in increased competition and pricing pressures. The market is also characterized by ongoing efforts to improve manufacturing processes and reduce costs, as well as increasing regulatory scrutiny to ensure the safety and quality of generic drugs.

In addition, there is growing interest in the development of complex generic drugs, such as biosimilars, which are highly similar to biologic drugs and have the potential to offer significant cost savings to patients. The increasing focus on specialty drugs and the development of complex generics is expected to drive further growth in the global generic drug market in the coming years.

Generic Drugs Market Segmentations

Market Breakup by Brand

- Pure Generic
- Branded Generic

Market Breakup by Indications

- Central Nervous System (CNS)
- Cardiovascular
- Dermatology
- Oncology
- Respiratory
- Others

Market Breakup by Route of Administration

- Oral
- Topical
- Parenteral
- Others

Market Breakup by End User

- Hospitals
- Homecare
- Specialty Centers
- Others

Market Breakup by Distribution Channel

- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy

Market Breakup by Region

- North America
 - United States of America
 - Canada
- Europe
 - United Kingdom
 - Germany
 - France
 - Italy

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

-[]Others

-[]Asia Pacific

-[]China

-[]Japan

-[]India

-[]ASEAN

-[]Australia

-[]Others

-[]Latin America

-[]Brazil

-[]Argentina

-[]Mexico

-[]Others

-[]Middle East and Africa

-[]Saudi Arabia

-[]United Arab Emirates

-[]Nigeria

-[]South Africa

-[]Others

Key Trends in the Generic Drugs Market

Some key trends in the generic drug market are:

-[]Increasing demand for cost-effective drugs: The rising healthcare expenditure is driving the demand for generic drugs, which are more affordable than branded drugs. As governments and insurance companies push for cost-effective alternatives, the demand for generic drugs is expected to increase.

-[]Patent expirations: As patents for major branded drugs expire, it provides an opportunity for generic drug manufacturers to enter the market. The loss of exclusivity allows generic drug manufacturers to produce and market a cheaper version of the drug, leading to increased competition.

-[]Growth in the biologics market: Biologic drugs, which are more complex and expensive to manufacture, are now facing patent expirations. This presents an opportunity for generic drug manufacturers to enter the market and offer more affordable alternatives.

-[]Regulatory changes: Government regulations around the world are pushing for more widespread use of generic drugs, which is expected to increase demand. For example, the FDA has launched initiatives to expedite the review process for generic drugs, making it easier for them to enter the market.

-[]Increasing consolidation: The generic drug market has seen increasing consolidation, with larger companies acquiring smaller ones to increase their market share. This trend is expected to continue, with larger companies seeking to expand their portfolios and global presence.

Generic Drugs Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

-[]Teva Pharmaceuticals Industries Ltd.

-[]Mylan NV

-[]Novartis AG

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- Pfizer Inc.
- Sun Pharmaceutical Industries Ltd.
- Fresenius SE & Co. KGaA
- Lupin
- Endo International plc.
- Aurobindo Pharma
- Novartis AG
- Hikma Pharmaceuticals PLC.
- STADA Arzneimittel AG
- 13. Eli Lilly and Company
- 14. Aspen Holdings

Table of Contents:

- 1 Preface
 - 1.1 Objectives of the Study
 - 1.2 Key Assumptions
 - 1.3 Report Coverage - Key Segmentation and Scope
 - 1.4 Research Methodology
- 2 Executive Summary
- 3 Global Generic Drug Market Overview
 - 3.1 Global Generic Drug Market Historical Value (2016-2022)
 - 3.2 Global Generic Drug Market Forecast Value (2023-2031)
- 4 Global Generic Drug Market Landscape
 - 4.1 Global Generic Drug Landscape
 - 4.1.1 Analysis by Year of Establishment
 - 4.1.2 Analysis by Company Size
 - 4.1.3 Analysis by Region
 - 4.2 Global Generic Drug Product Landscape
 - 4.2.1 Analysis by Brand
 - 4.2.2 Analysis by Indications
 - 4.2.3 Analysis by Route of Administration
- 5 Global Generic Drug Market Dynamics
 - 5.1 Market Drivers and Constraints
 - 5.2 SWOT Analysis
 - 5.3 Porter's Five Forces Model
 - 5.4 Key Demand Indicators
 - 5.5 Key Price Indicators
 - 5.6 Industry Events, Initiatives, and Trends
 - 5.7 Value Chain Analysis
- 6 Global Generic Drug Market Segmentation
 - 6.1 Global Generic Drug Market by Brand
 - 6.1.1 Market Overview
 - 6.1.2 Pure Generic
 - 6.1.3 Branded Generic
 - 6.2 Global Generic Drug Market by Indications

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 6.2.1 Market Overview
- 6.2.2 Central Nervous System (CNS)
- 6.2.3 Cardiovascular
- 6.2.4 Dermatology
- 6.2.5 Oncology
- 6.2.6 Respiratory
- 6.2.7 Others
- 6.3 Global Generic Drug Market by Route of Administration
 - 6.3.1 Market Overview
 - 6.3.2 Oral
 - 6.3.3 Topical
 - 6.3.4 Parenteral
 - 6.3.5 Others
- 6.4 Global Generic Drug Market by End User
 - 6.4.1 Market Overview
 - 6.4.2 Hospitals
 - 6.4.3 Homecare
 - 6.4.4 Specialty Centers
 - 6.4.5 Others
- 6.5 Global Generic Drug Market by Distribution Channel
 - 6.5.1 Market Overview
 - 6.5.2 Hospital Pharmacy
 - 6.5.3 Online Pharmacy
 - 6.5.4 Retail Pharmacy
- 6.6 Global Generic Drug Market by Region
 - 6.6.1 Market Overview
 - 6.6.2 North America
 - 6.6.3 Europe
 - 6.6.4 Asia Pacific
 - 6.6.5 Latin America
 - 6.6.6 Middle East and Africa
- 7 North America Generic Drug Market
 - 7.1 Market Share by Country
 - 7.2 United States of America
 - 7.3 Canada
- 8 Europe Generic Drug Market
 - 8.1 Market Share by Country
 - 8.2 United Kingdom
 - 8.3 Germany
 - 8.4 France
 - 8.5 Italy
 - 8.6 Others
- 9 Asia Pacific Generic Drug Market
 - 9.1 Market Share by Country
 - 9.2 China
 - 9.3 Japan
 - 9.4 India

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 9.5 ASEAN
- 9.6 Australia
- 9.7 Others
- 10 Latin America Generic Drug Market
 - 10.1 Market Share by Country
 - 10.2 Brazil
 - 10.3 Argentina
 - 10.4 Mexico
 - 10.5 Others
- 11 Middle East and Africa Generic Drug Market
 - 11.1 Market Share by Country
 - 11.2 Saudi Arabia
 - 11.3 United Arab Emirates
 - 11.4 Nigeria
 - 11.5 South Africa
 - 11.6 Others
- 12 Patent Analysis
 - 12.1 Analysis by Type of Patent
 - 12.2 Analysis by Publication year
 - 12.3 Analysis by Issuing Authority
 - 12.4 Analysis by Patent Age
 - 12.5 Analysis by CPC Analysis
 - 12.6 Analysis by Patent Valuation
 - 12.7 Analysis by Key Players
- 13 Grants Analysis
 - 13.1 Analysis by year
 - 13.2 Analysis by Amount Awarded
 - 13.3 Analysis by Issuing Authority
 - 13.4 Analysis by Grant Application
 - 13.5 Analysis by Funding Institute
 - 13.6 Analysis by NIH Departments
 - 13.7 Analysis by Recipient Organization
- 14 Clinical Trials Analysis
 - 14.1 Analysis by Trial Registration Year
 - 14.2 Analysis by Trial Status
 - 14.3 Analysis by Trial Phase
 - 14.4 Analysis by Therapeutic Area
 - 14.5 Analysis by Geography
- 15 Funding Analysis
 - 15.1 Analysis by Funding Instances
 - 15.2 Analysis by Type of Funding
 - 15.3 Analysis by Funding Amount
 - 15.4 Analysis by Leading Players
 - 15.5 Analysis by Leading Investors
 - 15.6 Analysis by Geography
- 16 Partnership and Collaborations Analysis
 - 16.1 Analysis by Partnership Instances

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 16.2 Analysis by Type of Partnership
- 16.3 Analysis by Leading Players
- 16.4 Analysis by Geography
- 17 Regulatory Framework
 - 17.1 Regulatory Overview
 - 17.1.1 US FDA
 - 17.1.2 EU EMA
 - 17.1.3 INDIA CDSCO
 - 17.1.4 JAPAN PMDA
 - 17.1.5 Others
- 18 Supplier Landscape
 - 18.1 Teva Pharmaceuticals Industries Ltd.
 - 18.1.1 Financial Analysis
 - 18.1.2 Product Portfolio
 - 18.1.3 Demographic Reach and Achievements
 - 18.1.4 Mergers and Acquisitions
 - 18.1.5 Certifications
 - 18.2 Mylan NV
 - 18.2.1 Financial Analysis
 - 18.2.2 Product Portfolio
 - 18.2.3 Demographic Reach and Achievements
 - 18.2.4 Mergers and Acquisitions
 - 18.2.5 Certifications
 - 18.3 Novartis AG
 - 18.3.1 Financial Analysis
 - 18.3.2 Product Portfolio
 - 18.3.3 Demographic Reach and Achievements
 - 18.3.4 Mergers and Acquisitions
 - 18.3.5 Certifications
 - 18.4 Pfizer Inc.
 - 18.4.1 Financial Analysis
 - 18.4.2 Product Portfolio
 - 18.4.3 Demographic Reach and Achievements
 - 18.4.4 Mergers and Acquisitions
 - 18.4.5 Certifications
 - 18.5 Sun Pharmaceutical Industries Ltd.
 - 18.5.1 Financial Analysis
 - 18.5.2 Product Portfolio
 - 18.5.3 Demographic Reach and Achievements
 - 18.5.4 Mergers and Acquisitions
 - 18.5.5 Certifications
 - 18.6 Fresenius SE & Co. KGaA
 - 18.6.1 Financial Analysis
 - 18.6.2 Product Portfolio
 - 18.6.3 Demographic Reach and Achievements
 - 18.6.4 Mergers and Acquisitions
 - 18.6.5 Certifications

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 18.7 Lupin
 - 18.7.1 Financial Analysis
 - 18.7.2 Product Portfolio
 - 18.7.3 Demographic Reach and Achievements
 - 18.7.4 Mergers and Acquisitions
 - 18.7.5 Certifications
- 18.8 Endo International plc.
 - 18.8.1 Financial Analysis
 - 18.8.2 Product Portfolio
 - 18.8.3 Demographic Reach and Achievements
 - 18.8.4 Mergers and Acquisitions
 - 18.8.5 Certifications
- 18.9 Aurobindo Pharma
 - 18.9.1 Financial Analysis
 - 18.9.2 Product Portfolio
 - 18.9.3 Demographic Reach and Achievements
 - 18.9.4 Mergers and Acquisitions
 - 18.9.5 Certifications
- 18.10 Novartis AG
 - 18.10.1 Financial Analysis
 - 18.10.2 Product Portfolio
 - 18.10.3 Demographic Reach and Achievements
 - 18.10.4 Mergers and Acquisitions
 - 18.10.5 Certifications
- 18.11 Hikma Pharmaceuticals PLC.
 - 18.11.1 Financial Analysis
 - 18.11.2 Product Portfolio
 - 18.11.3 Demographic Reach and Achievements
 - 18.11.4 Mergers and Acquisitions
 - 18.11.5 Certifications
- 18.12 STADA Arzneimittel AG
 - 18.12.1 Financial Analysis
 - 18.12.2 Product Portfolio
 - 18.12.3 Demographic Reach and Achievements
 - 18.12.4 Mergers and Acquisitions
 - 18.12.5 Certifications
- 18.13 Eli Lilly and Company
 - 18.13.1 Financial Analysis
 - 18.13.2 Product Portfolio
 - 18.13.3 Demographic Reach and Achievements
 - 18.13.4 Mergers and Acquisitions
 - 18.13.5 Certifications
- 18.14 Aspen Holdings
 - 18.14.1 Financial Analysis
 - 18.14.2 Product Portfolio
 - 18.14.3 Demographic Reach and Achievements
 - 18.14.4 Mergers and Acquisitions

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

18.14.5 Certifications

19 Global Generic Drug Market - Distribution Model (Additional Insight)

19.1 Overview

19.2 Potential Distributors

19.3 Key Parameters for Distribution Partner Assessment

20 Key Opinion Leaders (KOL) Insights (Additional Insight)

21 Company Competitiveness Analysis (Additional Insight)

21.1 Very Small Companies

21.2 Small Companies

21.3 Mid-Sized Companies

21.4 Large Companies

21.5 Very Large Companies

22 Payment Methods (Additional Insight)

22.1 Government Funded

22.2 Private Insurance

22.3 Out-of-Pocket

Global Generic Drugs Market Report and Forecast 2023-2031

Market Report | 2023-05-06 | 147 pages | EMR Inc.

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$5999.00
	Five User License	\$7999.00
	Corporate License	\$9999.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

☐ ** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-06"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com